# US 2024/0200098 A1 · Controllable Transcription

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200098 A1
- Document ID: US20240200098A1
- Status: Published application
- Kind: A1
- Application number: 18/543,249
- Filed: 2023-12-18
- Published: 2024-06-20
- Earliest claimed: 2016-11-24
- Assignees: Cambridge Enterprise Limited (GB/GB)
- Applicants: Cambridge Enterprise Limited (GB/GB)
- Inventors: Ludovic Vallier; Mark Kotter; Matthias Pawlowski; Alessandro Bertero; Daniel Ortmann
- Web page: https://patentgrep.com/patent/US20240200098A1

## CPC

- C12N 15/85: for animal cells
- C12N 15/86: Viral vectors
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}
- C12N 5/0607: {Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N5/0696)}
- C12N 5/0622: {Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells}
- C12N 5/0658: {Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2506/02: from embryonic cells
- C12N 2506/03: from non-embryonic pluripotent stem cells
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N 2830/003: tet inducible
- G01N 2800/00: Detection or diagnosis of diseases
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to a stable method for introducing at least one inducible cassette into a cell, and permitting controllable transcription from within that inducible cassette. The method may be used for any cell type, from any eukaryotic organism, but has a particular application in the introduction of inducible cassettes into pluripotent stem cells, such as animal or human pluripotent stem cells (hPSCs). The inducible cassette is controllably inserted in such a way to ensure that the genetic material it contains is not silenced or subject to negative influences from the insertion site, and transcription of the genetic material is controlled.

## Claims

### Claim 1

A method for the production of a myocyte from a pluripotent stem cell, comprising the steps of:
a) inserting into a pluripotent stem cell a gene encoding a transcriptional regulator protein into a first genetic safe harbour site; and
b) inserting into the pluripotent stem cell a MYOD1 gene operably linked to an inducible promoter into a second genetic safe harbour site;
wherein the inducible promoter is regulated by the transcriptional regulator protein;
wherein the first and second genetic safe harbour sites are different; and
wherein the pluripotent stem cell is an animal cell.

### Claim 2 (depends on 1)

The method of claim 1, further comprising following step (b) culturing the cell in the presence of retinoic acid.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cell is a mammalian, marsupial, non-human primate, camelid, or livestock animal cell.

### Claim 4 (depends on 1)

The method of claim 1, wherein the animal cell is from a livestock animal.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cell is from a pig or from cattle.

### Claim 6 (depends on 1)

The method of claim 1, wherein the method is for programming of the pluripotent stem cell into a mature cell.

### Claim 7 (depends on 1)

The method of claim 1, wherein the method is for programming of the pluripotent stem cell into a myocyte.

### Claim 8 (depends on 1)

The method of claim 1, wherein said transcriptional regulator protein is selected from the group consisting of: a reverse tetracycline transactivator protein (rtTa), a Tetracycline repressor (TetR), a VgEcR synthetic receptor, a hybrid transcriptional regulator protein comprising a DNA binding domain from the yeast GAL4 protein, a truncated ligand binding domain from the human progesterone receptor, and an activation domain from the human NF-κB.

### Claim 9 (depends on 1)

The method of claim 1, wherein said transcriptional regulator protein is a reverse tetracycline transactivator protein (rtTa) or a derivative thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein the activity of rtTA is controlled by tetracycline or a derivative thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein activity of the rtTA is controlled by doxycycline.

### Claim 12 (depends on 1)

The method of claim 1, wherein the inducible promoter includes a Tet Responsive Element (TRE).

### Claim 13 (depends on 1)

The method of claim 1, wherein said first and second genomic safe harbour sites are selected from any two of the hROSA26 locus, the AAVS1 locus, the CLYBL gene or the CCR5 gene.

### Claim 14 (depends on 1)

The method of claim 1, wherein additional genetic material is inserted at the first and/or second genomic safe harbour sites.

### Claim 15 (depends on 1)

The method of claim 1, further comprising inserting additional genetic material at the first and/or second genomic safe harbour sites, said additional genetic material selected from the group consisting of:
a) a suicide gene;
b) a selectable marker;
c) a reporter gene; and
d) a gene for a non-coding RNA.

### Claim 16 (depends on 1)

A cell obtainable by the method according to claim 1.

### Claim 17 (depends on 16)

A method for tissue engineering, comprising the cell of claim 16.

### Claim 18 (depends on 17)

The method of claim 17, wherein the method is for producing cultured meat.

### Claim 19

A method for knocking out an endogenous gene in a cell, comprising the following steps:
a) inserting into the cell a gene encoding a transcriptional regulator protein and a gene encoding Cas9 into a first genetic safe harbour site; and
b) inserting into the cell an inducible cassette comprising a guide RNA operably linked to an inducible promoter into a second genetic safe harbour site;
wherein said promoter is regulated by the transcriptional regulator protein;
wherein said gRNA sequence targets the endogenous gene; and
wherein said first and second genetic safe harbour sites are different.

### Claim 20 (depends on 19)

The method of claim 19, wherein the cell is an animal cell.

### Claim 21 (depends on 19)

The method of claim 19, wherein the cell is a mammalian, marsupial, non-human primate, camelid, or livestock cell.

### Claim 22 (depends on 19)

The method of claim 19, wherein the cell is from a pig or from cattle.

### Claim 23 (depends on 19)

The method of claim 19, wherein said transcriptional regulator protein is selected from the group consisting of: a reverse tetracycline transactivator protein (rtTa), a Tetracycline repressor (TetR), a VgEcR synthetic receptor, a hybrid transcriptional regulator protein comprising a DNA binding domain from the yeast GAL4 protein, a truncated ligand binding domain from the human progesterone receptor, and an activation domain from the human NF-κB.

### Claim 24 (depends on 19)

The method of claim 19, wherein said transcriptional regulator protein is a reverse tetracycline transactivator protein (rtTa) or a derivative thereof.

### Claim 25 (depends on 24)

The method of claim 24, wherein the activity of rtTA is controlled by tetracycline or a derivative thereof.

### Claim 26 (depends on 19)

The method of claim 19, wherein the inducible promoter includes a Tet Responsive Element (TRE).
